Tango Therapeutics Inc. vs TotalEnergies SE — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while TotalEnergies SE trades at $90 (market cap $196.57B). The key difference: TotalEnergies SE is far larger — about 52.4× Tango Therapeutics Inc.'s market cap, and TotalEnergies SE pays a 4.76% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and TotalEnergies SE for 91 Days on average.
| TNGX | TTE | |
|---|---|---|
Market Cap | $3.75B | $196.57B |
Volume | 9,619,106 | 2,606,285 |
Sector | Health | Energy |
52-Week High | $32.90 | $93.60 |
52-Week Low | $7.50 | $60.44 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $2.77B | $227.56B |
Dividend Yield | — | 4.76% |
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
TotalEnergies (TTE) trades at $89.64, up 1.44% today, with a bullish technical outlook and strong analyst support. The stock shows robust fundamentals with a P/E of 11.13 and net income margin of 9.08%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights a $10B investment in Argentina and a $2.5B Q4 share buyback increase, reinforcing growth commitments. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending.
The outlook for TTE is positive, driven by strategic investments and shareholder returns, but faces risks from volatile energy prices and execution challenges. Wall Street consensus is bullish with a $95.33 price target, though investors should monitor oil price fluctuations and geopolitical factors that could impact profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →